PT  - JOURNAL ARTICLE
AU  - Nierengarten, Mary Beth
ED  - Fehlings, Michael G.
TI  - RISCIS: Phase 3 Trial on Off-Label Use of Riluzole for SCI
DP  - 2015 Feb 01
TA  - MD Conference Express
PG  - 14--15
VI  - 14
IP  - 50
4099  - http://mdc.sagepub.com/content/14/50/14.2.short
4100  - http://mdc.sagepub.com/content/14/50/14.2.full
AB  - Acute spinal cord injury (SCI) is a devastating injury that can be the result of varying traumatic mechanisms. While early surgical decompression and different pharmacological agents have been advocated over the years, it is still unclear how effective these treatments are in improving neurological outcomes. This article discusses the ongoing Riluzole in Spinal Cord Injury Study [RISCIS; NCT01597518], a phase 3, multicenter, double-blind, randomized controlled trial to evaluate the efficacy and safety of off-label use of riluzole to treat patients with acute SCI.